Ocugen Inc. Insider Trading

OCGN

⊜ Compare

Last 12 months

Insiders bought 26K and sold $1.09M on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$1.06M

1 buy · 2 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

1 / 1

executives and directors

Last open-market buy

Jun 2026

Jun 15, 2026

Get an email when OCGN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 9	Shankar Musunuri Chief Executive Officer	Sold10b5-1 plan 2 parts	525,991	$0.95 average	500K	9.4%	Form 4
Sep 9	Shankar Musunuri Chief Executive Officer	Sold10b5-1 plan 2 parts	525,991	$1.12 average	589K	8.6%	Form 4
Jun 15	Treerita Essalima Johnson-Greene Chief Financial Officer	Bought	21,000	$1.23	26K	4.2%	Form 4
Nov 26, 2024	Prabhavathi Fernandes Director	Bought	10,000	$0.91	9K	New	Form 4
Nov 22, 2024	Kirsten Castillo Director	Bought	25,000	$0.91	23K	50%	Form 4

Oct 910b5-1 plan
Shankar Musunuri
Chief Executive Officer · sold 525,991 at avg $0.95
500K
9.4% of stake
Sep 910b5-1 plan
Shankar Musunuri
Chief Executive Officer · sold 525,991 at avg $1.12
589K
8.6% of stake
Jun 15
Treerita Essalima Johnson-Greene
Chief Financial Officer · bought 21,000 at $1.23
26K
4.2% of stake
Nov 26, 2024
Prabhavathi Fernandes
Director · bought 10,000 at $0.91
9K
New position
Nov 22, 2024
Kirsten Castillo
Director · bought 25,000 at $0.91
23K
50% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch OCGN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with OCGN

CompareIntrinsic value

PRMEPrime Medicine Inc.

$4.97+9.23%0

CRISCuris Inc.

$1.11+56.34%25

DBVTDBV Technologies S.A.

$9.94-1.68%10

DYAIDyadic International Inc.

$0.37+1.86%36

ALGSAligos Therapeutics Inc.

$5.02+5.68%10

TSHATaysha Gene Therapies Inc.

$4.36+6.60%40

ATRAAtara Biotherapeutics, Inc.

$8.37+2.07%15

CGONCG Oncology, Inc.

$67.71+5.70%40

Held by ETFs

OCGN is in 11 US ETFs. The largest of them, with OCGN's weight in each:

Spot a number that looks wrong? Check it in OCGN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing OCGN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.